Mariner
DSGN icon

Mariner’s Design Therapeutics DSGN Stock Holding History

Mariner’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Buy
13,066
+244
+2% +$2.47K ﹤0.01% 3260
2025
Q4 		$120K Sell
12,822
-3,259
-20% -$25.5K ﹤0.01% 3296
2025
Q3 		$121K Buy
16,081
+341
+2% +$1.71K ﹤0.01% 3323
2025
Q2 		$53K Buy
15,740
+269
+2% +$1.01K ﹤0.01% 3340
2025
Q1 		$59.7K Sell
15,471
-786
-5% -$3.75K ﹤0.01% 3280
2024
Q4 		$100K Buy
16,257
+129
+0.8% +$747 ﹤0.01% 3189
2024
Q3 		$86.7K Sell
16,128
-2,546
-14% -$12K ﹤0.01% 3115
2024
Q2 		$62.6K Hold
18,674
– – ﹤0.01% 3019
2024
Q1 		$75.3K Buy
+18,674
New +$49.9K ﹤0.01% 2978

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Mariner's DSGN Position: Q1 2026 in Review

Mariner increased its Design Therapeutics (DSGN) stake by 1.9% in Q1 2026, buying an estimated $2.47K and bringing the position to 13,066 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #3260.

Mariner first reported a position in DSGN in Q1 2024 and has held it in 9 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Mariner held 13,066 shares of Design Therapeutics worth $139K as of Q1 2026.
  • Mariner bought 244 Design Therapeutics shares in Q1 2026, an estimated $2.47K.
  • Design Therapeutics made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3260 holding.
  • Mariner first reported a position in Design Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.